Keryx Biopharmaceuticals Inc. (KERX)
Oncology Corporate Profile
- Products & Overview
- Recent News
HQ Location
750 Lexington AvenueNew York, NY 10022
Company Description
Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer.
Website: http://www.keryx.com
Commercial Products
This company does not have any commercial productsPipeline Products
- Brand
- Generic
- Investigational
| Brand / Product | Class | Area of Study | Phase | Partnership |
|---|---|---|---|---|
| perifosine / KRX-0401 | AKT inhibitor | 2nd line metastatic Renal cell carcinoma (RCC) | II | AEterna Zentaris |
| perifosine / KRX-0401 | AKT inhibitor | 2nd line Multiple Myeloma | II | AEterna Zentaris |
| perifosine / KRX-0401 | AKT inhibitor | Gastrointestinal Stromal Tumor (GIST) | II | AEterna Zentaris |
| perifosine / KRX-0401 | AKT inhibitor | Refractory metastatic Colorectal cancer | II | AEterna Zentaris |
| perifosine / KRX-0401 | AKT inhibitor | Recurrent Pediatric cancer | I | AEterna Zentaris |
View additional information on product candidates here »
Recent News Headlines
[AP] - Keryx Biopharmaceuticals reported a second-quarter loss as it ramped up spending on drug candidates. Keryx has no products on the market. It posted a profit a year ago due to $18.3 million in revenue from two of its partners.
[PR Newswire] - Keryx Biopharmaceuticals, Inc. , a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease, today announced that a conference call will be held on Monday, August 9, 2010 at 8:30 a.m.
[Wall Street Transcript] - 67 WALL STREET, New York - August 4, 2010 - The Wall Street Transcript has recently published its Biotechnology & Pharmaceuticals Report offering a timely review of the sector to serious investors and industry executives. This special feature contains expert industry commentary through in-depth interviews with public company CEOs, Equity Analysts and Money Managers. <b>The full issue is available by calling (212) 952-7433 or via <a href="http://www.twst.com/tt/info/yhoo/info1939.htm">The Wall Street Transcript Online</a></b>.
[Business Wire] - NEW YORK----LifeSci Advisors, LLC., a leading provider of investment research and investor relations services in the life sciences sector, today announced that it has initiated coverage on Keryx Biopharmaceuticals , a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease.
[AP] - Keryx Biopharmaceuticals Inc. said Wednesday it has appointed retired Pfizer executive Dr. Joseph Feczko to its board of directors.
[PR Newswire] - Keryx Biopharmaceuticals, Inc. today announced the appointment of Joseph Feczko, M.D. to the Company's Board of Directors.
[GlobeNewswire] - DALLAS -- MicroStockProfit.com announces an investment report featuring Keryx Biopharmaceuticals Inc. . The report includes financial, comparative and investment analyses, and recent company news that you need to know to make an educated investment decision.
Keryx Biopharmaceuticals Inc. said Wednesday that its experimental cancer drug perifosine received orphan drug status as a treatment for neuroblastoma, a cancer that affects the nervous system and mostly strikes young children.
Keryx Biopharmaceuticals Inc. said Wednesday that its experimental cancer drug perifosine received orphan drug status as a treatment for neuroblastoma, a cancer that affects the nervous system and mostly strikes young children.
Small-cap biotechs Codexis, Keryx Biopharmaceuticals and Aeterna Zentaris move into the spotlight as drug stocks edge higher.